Patients often use AI to read test results, but AI can misinterpret data and cause panic. Learn why human context remains critical.
|Videos|September 12, 2016
Melanoma & Men: Don’t Wait to Get Checked
Author(s)Melanoma Foundation of New England
Advertisement
We see the highest rates of melanoma related mortality in men over the age of 50. Why is this? Often times men are not getting their skin checked on an annual basis, and even when a change occurs, it often goes unnoticed. Older males are in a high risk group for melanoma. Hear first hand experiences and learn why you should schedule a skin exam soon.
Advertisement
Related to this article
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.
KEYNOTE-564 data show adjuvant pembrolizumab maintains DFS and OS benefits in ccRCC. Review key nursing takeaways and safety outcomes.
ASTRO updated its pancreatic cancer radiation guideline. Dr Michael Chuong shares direct takeaways on nursing roles in multidisciplinary care.
NCCN survey data show 100% of cancer centers face drug shortages, with ifosfamide and carboplatin critical.
Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
FDA approves cabozantinib capsules for RCC, HCC, and epNET. Review key dosing conversions and safety guidelines for oncology nursing practice.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Oncology Experts Discuss On-Body Subcutaneous Isatuximab in Multiple Myeloma
2
Why Using AI to Interpret Mammogram Results Can Cause Unnecessary Panic
3
KEYNOTE-564 5-Year Data: Adjuvant Pembrolizumab Benefits ccRCC
4
Updated ASTRO Pancreatic Guidelines: Key Takeaways for Oncology Nurses
5